-
Abbott Laboratories Expands Global Diabetes Care with New Kilkenny Facility
•
Abbott Laboratories (NYSE: ABT), a leading US healthcare company, has announced the opening of its state-of-the-art manufacturing facility in Kilkenny, Ireland. This new site, which serves as a global manufacturing center of excellence for Abbott’s diabetes care business, is expected to create over 800 new jobs. Details of the Kilkenny…
-
Abbott Laboratories Posts 9.4% Q3 Sales Growth, Driven by Medical Devices and Pharmaceuticals
•
Abbott Laboratories (NYSE: ABT), a U.S.-based healthcare giant, has reported its financial results for the third quarter of 2024, highlighting a robust 9.4% year-on-year sales growth in constant currency terms, reaching USD 10.64 billion. The Established Pharmaceuticals segment recorded a 2.7% rise in Q3 to USD 1.406 billion, with emerging…
-
OrbusNeich Medical Group Partners with Abbott’s CSI as Sole Distributor
•
Shenzhen-based vascular intervention specialist OrbusNeich Medical Group Ltd (HKG: 6929) has announced a significant distribution agreement with Cardiovascular Systems Inc. (CSI), a subsidiary of U.S. giant Abbott Laboratories (NYSE: ABT). Under this agreement, CSI will serve as the exclusive distributor of OrbusNeich’s coronary and peripheral balloon products in the United…
-
Abbott Laboratories Reports Q2 2024 Sales Growth of 9.3%, Led by Medical Devices and Diabetes Sales
•
Abbott Laboratories (NYSE: ABT), a global healthcare giant based in the US, has reported its financial results for the second quarter of 2024, highlighting a 9.3% year-on-year (YOY) increase in sales, reaching USD 10.4 billion in constant currency terms. The Medical Devices segment was the top performer, marking a 12.1%…
-
Zai Lab Ltd Appoints New Greater China CCO as Liang Yi Exits
•
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the appointment of Zhu Tong as the new Greater China Chief Commercial Officer (CCO), succeeding Liang Yi, who is departing from his role as both CCO and President of Greater China. Liang’s departure will become official on April 30. Zhu Tong’s…
-
Abbott Reports Q1 2024 Organic Sales Growth of 4.7%, Led by Pharmaceuticals and Devices
•
Abbott (NYSE: ABT), a global healthcare giant, has this week announced its financial results for the first quarter of 2024. The company reported a 4.7% year-on-year (YOY) increase in global sales on an organic basis, reaching USD 10.0 billion. Excluding the impact of reduced demand for SARS-CoV-2 tests, the growth…
-
AbbVie CEO Rick González to Retire, Succeeded by Robert A. Michael
•
AbbVie (NYSE: ABBV), a leading US pharmaceutical company, has announced that Rick González, who has been at the helm since the company’s separation from Abbott (NYSE: ABT) in 2013, will retire from his role as CEO. González will transition to the position of executive chairman of the board of directors,…
-
Abbott Reports Mixed 2023 Results with Q4 Growth Offsetting Full-Year Decline
•
US healthcare company Abbott (NYSE: ABT) has released its financial results for the fourth quarter and full year of 2023. The company’s Q4 global sales increased by 2.1% year-on-year (YOY) in constant currency terms to USD 10.24 billion, although for the full year, sales declined by 6.2% to USD 40.1…
-
Abbott Initiates Clinical Study for Volt PFA System in Australia for Cardiac Arrhythmias
•
Abbott (NYSE: ABT) has announced that the first patients have been treated with its Volt pulsed field ablation (PFA) system as part of a clinical study in Australia. The study is designed to evaluate the safety and effectiveness of the device in treating common cardiac arrhythmias such as atrial fibrillation…
-
Abbott Reports 8.7% Drop in Q3 2023 Global Sales, Hit by Lower SARS-CoV-2 Test Demand
•
Abbott (NYSE: ABT) published its Q3 2023 financial results this week, reporting a 8.7% year-on-year (YOY) decline in global sales on an organic basis to USD 29.9 billion over the first three quarters. The decrease was primarily attributed to significantly reduced demand for SARS-CoV-2 tests, which led to a 42.1%…
-
Abbott Expands Biosimilars Portfolio with mAbxience In-License Agreement
•
Abbott (NYSE: ABT) has announced the in-licensing of several biosimilar drugs from Spain-based biotechnology firm mAbxience for select markets in Latin America, Southeast Asia, the Middle East, and Africa. mAbxience, which had its majority stake acquired by German group Fresenius (ETR: FRE) from Argentina-based Insud Pharma last year, specializes in…
